-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
People with Parkinson's disease (PD) had an almost 6-fold increased risk of developing cognitive impairment and dementia (PDD) compared to age-matched
Figure 1: Cover art of the paper
However, 24% of patients with PD-MCI returned to normal cognitive function
To date, studies have shown that progress in IADL is associated with a deterioration in some cognitive indicators and future cognitive test performance, but the results predicting cognitive diagnosis are uncertain due to the lack of longitudinal studies
On the cross-section, not all studies have confirmed a direct link between cognition and function in PD,10,11 which means that not all instruments are suitable for detecting cognitive-driven IADLs and may be confused
They hypothesized that patients with both PD-MCI and cognitive IADL disorders had a higher
First: define the baseline phenotype associated with cognitive IADL impairment, with the expectation of decreased cognitive performance, genetic risk variants associated with cognitive impairment, and high ratios of cerebrospinal fluid (CSF) biomarkers;
Figure 2: Graph of the paper results
Second: The study studied the progress of functions over time reflected by changes in FAQ subscores, assuming that patients with baseline classification of PD-MCI or cognitive IADL disorder had higher
They conducted an observational longitudinal study using cognitive and clinical scores, as well as genetic and CSF biomarkers
Of the 268 PD patients assessed at baseline, 108 (40.
HR with baseline cognitive IADL disorder (n=37) to dementia was described as higher than PD-MCI, but highest among patients with both markers (HR=12.
In the follow-up sample, nearly half of the patients (n=10, 47.
Becker S, Bode M, Brockmann K, et al.